Stock Price Quote

SMS PHARMACEUTICALS LTD.

NSE : SMSPHARMABSE : 532815ISIN CODE : INE812G01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE318.95-2.3 (-0.72 %)
PREV CLOSE ( ) 321.25
OPEN PRICE ( ) 321.00
BID PRICE (QTY) 318.95 (4)
OFFER PRICE (QTY) 319.40 (28)
VOLUME 8327
TODAY'S LOW / HIGH ( )315.00 327.35
52 WK LOW / HIGH ( )175 335.25
NSE318.15-2.75 (-0.86 %)
PREV CLOSE( ) 320.90
OPEN PRICE ( ) 320.90
BID PRICE (QTY) 318.15 (69)
OFFER PRICE (QTY) 318.50 (71)
VOLUME 170512
TODAY'S LOW / HIGH( ) 314.50 322.95
52 WK LOW / HIGH ( )176.05 335
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-12 1987
Management Info
Ramesh Babu Potluri - Chairman Ramesh Babu Potluri - Managing Director
Registered Office

Address Plot No. 72, H. No. 8-2-334 / 3 & 4,Road No. 5, Opp. S B I Executive Enclave,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040 25259999

Email info@smspharma.com

Website www.smspharma.com

Registrars Details
Aarthi Consultants Pvt Ltd
1-2-285 ,Domalaguda,,Hyderabad
Listing : BSE, NSE

NEWS

04Dec SMS Pharmaceuticals informs about cred
Pursuant to 30 read with Schedule III of SEBI (Listing Obligations and D..
26Nov SMS Pharmaceuticals informs about pres
SMS Pharmaceuticals has informed that it enclosed the press release titl..
26Nov SMS Pharmaceuticals’ associate gets US
SMS Pharmaceuticals’ associate company -- VKT Pharma has received approv..
26Nov SMS Pharmaceuticals zooms as its assoc
SMS Pharmaceuticals is currently trading at Rs. 290.30, up by 16.30 poin..
06Nov SMS Pharmaceuticals informs about disc
SMS Pharmaceuticals has informed that it enclosed the disclosure under R..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit251.44683.81
Gross Profit 340.56 933.2
Operating Profit 498.131461.98
Net Sales 2424.37827.48

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Bharat Parenterals (BSE)
peergroup  1101.40 (3.81%)
M.Cap ( in Cr)759.08
Panacea Biotec (BSE)
peergroup  366.75 (10.75%)
M.Cap ( in Cr)2192.78
Lupin (BSE)
peergroup  2115.35 (1.68%)
M.Cap ( in Cr)96665.48
Emcure Pharma (BSE)
peergroup  1435.00 (1.85%)
M.Cap ( in Cr)27164.64
Aurobindo Pharma (BSE)
peergroup  1198.15 (2.19%)
M.Cap ( in Cr)69481.30

Shareholding Pattern

PROMOTERS 68.07%
NON-INSTITUTION 28.78%
MUTUAL FUNDS/UTI 2.88%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About SMS Pharmaceuticals Ltd.

SMS Pharmaceuticals Ltd. was incorporated in the year 1987. Its today's share price is 318.95. Its current market capitalisation stands at Rs 2985.63 Cr. In the latest quarter, company has reported Gross Sales of Rs. 8466.03 Cr and Total Income of Rs.7889.73 Cr. The company's management includes Suresh Kumar Gangavarapu, Sunkara Venkata Satya Shiva Prasad, Trilok Potluri, Vamsi Krishna Potluri, Shanti Sree Bolleni, Sarvepalli Srinivas, Shravan Kudaravalli, Ramesh Babu Potluri , Ramesh Babu Potluri , Thirumalesh Tumma.

It is listed on the BSE with a BSE Code of 532815 , NSE with an NSE Symbol of SMSPHARMA and ISIN of INE812G01025. It's Registered office is at Plot No. 72, H. No. 8-2-334 / 3 & 4,Road No. 5, Opp. S B I Executive Enclave,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are P Murali & Co, Rambabu & Co, Suryanarayana & Suresh

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.